Análisis de costo efectividad de ondansetrón para el tratamiento del vómito en niños menores de cinco años con gastroenteritis en Colombia

Atehortúa, Sara; Flórez, Iván D.; Ceballos, Mateo; Granados, Claudia; Orozco, Luis E.; Mejía, Aurelio

Mostrar el registro sencillo del registro

dc.rights.licence	Atribución-NoComercial 4.0 Internacional	*
dc.contributor.author	Atehortúa, Sara
dc.contributor.author	Flórez, Iván D.
dc.contributor.author	Ceballos, Mateo
dc.contributor.author	Granados, Claudia
dc.contributor.author	Orozco, Luis E.
dc.contributor.author	Mejía, Aurelio
dc.coverage.spatial	Colombia	spa
dc.date.accessioned	2020-03-30T20:24:27Z
dc.date.accessioned	2020-04-15T13:26:39Z
dc.date.available	2020-03-30T20:24:27Z
dc.date.available	2020-04-15T13:26:39Z
dc.date.created	2015-12
dc.identifier	https://www.valuehealthregionalissues.com/article/S2212-1099(14)00081-8/fulltext	spa
dc.identifier.issn	2212-1099 / 2212-1102 (Electrónico)	spa
dc.identifier.uri	http://hdl.handle.net/10554/47953
dc.format	PDF	spa
dc.format.mimetype	application/pdf	spa
dc.language	spa	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/	*
dc.source	Value in Health Regional Issue; Vol. 8 (2015)	spa
dc.subject	Colombia	spa
dc.subject	Costo-efectividad	spa
dc.subject	Diarrea	spa
dc.subject	Gastroenteritis	spa
dc.subject	Hospitalización	spa
dc.subject	Niños	spa
dc.subject	Ondansetrón	spa
dc.subject	Vómito	spa
dc.title	Análisis de costo efectividad de ondansetrón para el tratamiento del vómito en niños menores de cinco años con gastroenteritis en Colombia	spa
dc.type	info:eu-repo/semantics/article
dc.type.hasversion	http://purl.org/coar/version/c_ab4af688f83e57aa
dc.description.quartilescopus	Q2	spa
dc.identifier.doi	http://dx.doi.org/10.1016/j.vhri.2014.11.001	spa
dc.description.paginas	1-7	spa
dc.format.soporte	Papel / Electrónico	spa
dc.description.abstractenglish	Introduction Ondansetron reduces hospitalization rates for diarrhea and vomiting in children, but is not yet routinely used. Objective To estimate from a social perspective the relative cost-effectiveness of ondansetron for the treatment of vomiting in children with gastroenteritis and at risk of dehydration in Colombia. Methods Cost-effectiveness analysis from a social perspective, including direct medical costs and costs for caregivers. With a decision tree we compared costs and health outcomes of usual treatment without antiemetic to usual treatment plus ondansetron in children under 5 years with gastroenteritis and vomiting. Effectiveness of intervention was measured as reduction in hospitalization rates, and the time horizon of the model was the episode. Probabilities were obtained from clinical trials and systematic reviews, measurement of resources use was based on protocols and expert opinions, while unit costs were obtained from Colombian tariff manuals. We performed a survey to estimate indirect costs for caregivers (n=81) that included questions about wage loss, transportation, meals expenditures and other out-of-pocket payments. Deterministic and probabilistic sensitivity analyses were performed. Results Usual treatment plus ondansetron is a dominant strategy compared to usual treatment without antiemetic yielding fewer hospitalizations and saving $44.562 Colombian pesos (23,98USD) per episode. Ondansetron was dominant in 98,91% of simulations of the probabilistic analysis. Conclusions Ondansetron is a dominant intervention that reduces hospitalization rates and costs for health system and caregivers. We recommend assessing the inclusion of this drug in the Colombian Health Benefit Plan for the treatment of gastroenteritis in children under 5 years.	spa
dc.type.local	Artículo de revista	spa
dc.contributor.corporatename	Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística